Key result
Pigment epithelium-derived factor (PEDF) could defer the occurrence and progress of macrovascular complications in type 2 diabetes mellitus.
Why the study?
Does pigment epithelium-derived factor defer the occurrence and progress of macrovascular complications in type 2 diabetes mellitus?
Does pigment epithelium-derived factor defer the occurrence and progress of macrovascular complications in type 2 diabetes mellitus?
PEDF exerts multiple protective effects that may defer the occurrence and progression of macrovascular complications in type 2 diabetes mellitus.
May support PEDF pathways in T2DM macrovascular protection; leaves open confirmation via prospective trials before any practice change.
Pigment epithelium-derived factor (PEDF),a potent inhibitor of neovascularization,exerts neurotrophic,neuroprotective,and vascular permeability-regulative effects.In addition,PEDF not only ameliorates insulin resistance,but also inhibits inflammation,attenuates oxidation,suppresses proliferation and migration of vascular smooth muscle cells,inhibits angiogenesis,blocks thrombus formation,hinder the C-reactive protein,and so on.Consequently,PEDF could defer the occurrence and progress of macrovascular complications in type 2 diabetes mellitus.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2013) conducted a review in Type 2 diabetes mellitus with macroangiopathy. Pigment epithelium-derived factor (PEDF) was evaluated. Pigment epithelium-derived factor (PEDF) could defer the occurrence and progress of macrovascular complications in type 2 diabetes mellitus.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: